Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?

Cardiovascular Drugs and Therapy

Volumn 32, Issue 2, 2018, Pages 213-222

  Flores, Eduardo ^a,b   Santos Gallego, Carlos G ^b   Diaz Mejía, Nely ^c   Badimon, Juan Jose ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cardiac magnetic resonance; Cardiovascular diseases; Empagliflozin; Heart failure; SGLT 2 receptor inhibitors; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN; KETONE BODY; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM PROTON EXCHANGE PROTEIN; SULFONYLUREA DERIVATIVE; BIOLOGICAL MARKER;

ANTIDIABETIC ACTIVITY; CARDIOVASCULAR SYSTEM; DRUG EFFECT; DRUG MECHANISM; GLUCOSE HOMEOSTASIS; HEART MUSCLE METABOLISM; HUMAN; KIDNEY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; GLUCOSE BLOOD LEVEL; METABOLISM; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85045736351     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-018-6786-x     Document Type: Review

References (61)

1. Santos-Gallego CG, Picatoste B, Badimón JJ. Pathophysiology of acute coronary syndrome. Curr Atheroscler Rep. 2014 Apr;16(4):401.
2. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2019. Circulation. 2018.
3. Reusch JEB, Manson JE. Management of type 2 diabetes in 2017. JAMA. 2017;317:1015–6.
4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:2011–30.
5. Dalama B, Mesa J. New oral hypoglycemic agents and cardiovascular risk. Crossing the metabolic border. Rev Esp Cardiol. 2016;69(11):1088–97.
6. Defronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95.
7. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36:S127–38.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
9. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–9.
10. de Leeuw AE, de Boer RA. Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects. Eur Heart J Cardiovasc Pharmacother. 2016;2(4):244–55.
11. Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risk of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100.
12. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. Long-term follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1565–76.
13. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H, Miller M, Byington R, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.
14. Smith RJ, Goldfine AB, Hiatt WR. Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess? Diabetes Care. 2016 May;39(5):738–42.
15. Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5(1):6.
16. Stoll BJ, et al. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40:S64–74.
17. Zonszein J, Groop PH. Strategies for diabetes management: using newer oral combination therapies early in the disease. Diabetes Ther. 2016;7(4):621–39.
18. Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016 Oct;12(10):566–92.
19. Bain SC, Feher M, Russell-Jones D, Khunti K. Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK. Diabetes Obes Metab. 2016;18(12):1157–66.
20. Nissen SE, Wolski K. Rosiglitazone revisited: un updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170914:1191–1201.
21. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
22. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Philips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2003;26(11):2983–9.
23. Sattar N, Petrie MC, Zinman B, Januzzi JL. Novel diabetes drugs and the cardiovascular specialist. J Am Coll Cardiol. 2017;69(21):2646–56.
24. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a posiion statement of the american diabetes association and the european association for the study of diabetes. Diabetes Care. 2015;38(1):140–9.
25. Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014;16(1):30–7.
26. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
27. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.
28. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42.
29. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical. Cardiovasc Ther. 2014;32(4):147–58.
30. Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al. Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N Engl J Med. 2014;370(9):794–7.
31. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28.
32. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
33. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.
34. Fadini GP, Avogaro A. SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 2017;5(9):680–1.
35. Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18(4):317–32.
36. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
37. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
38. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.
39. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.
40. Bethel M, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105–13.
41. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012;8:495-502.
42. Lee YJ, Han HJ. Regulatory mechanisms of Na+/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl. 2007;106:S27–35.
43. American Diabetes Association. Standards of medical care in diabetes-2017 a bridged for primary care providers. Clin Diabetes. 2017;35(1):5–26.
44. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure. Circulation. 2017;136(17):1643–58.
45. Cefalu WT, Riddle MC. SGLT2 inhibitors: The latest “New kids on the block”! Diabetes Care. 2015;38(3):352–4.
46. Badimon JJ, Santos-Gallego CG, Badimon L. [Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?]. Rev Esp Cardiol 2010;63 Suppl 2:20–35.
47. Santos-Gallego CG. HDL: Quality or quantity? Atherosclerosis 2015;243(1):121–3.
48. Badimon JJ, Santos-Gallego CG. HDL Dysfunction: Is the Answer in the Sphinx's Riddle? J Am Coll Cardiol 2015;66(13):1486–8.
49. Santos-Gallego CG, Badimon JJ, Rosenson RS. Beginning to understand high-density lipoproteins. Endocrinol Metab Clin North Am 2014;43(4):913–47.
50. Santos-Gallego CG, Rosenson RS. Role of HDL in Those with Diabetes. Curr Cardiol Rep 2014;16(8):512.
51. Santos-Gallego CG, Giannarelli C, Badimon JJ. Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux. Curr Atheroscler Rep 2011;13(3):266–76
52. Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediatin analysis of the EMPA-REG OUTCOME. Diabetes Care. 2018;41(2):356–63.
53. Sato K, Kashiwaya Y, Keon CA, et al. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J 1995;9:651–8.
54. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108–14.
55. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39(7):1115–22.
56. Packer M. Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation. 2017;136(16):1548–59.
57. Packer M, Anker SD, Butler J, et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure proposal of a novel mechanism of action. JAMA Cardiol. 2017;2(9):1025–9.
58. Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018;61(3):722–6.
59. Baartscheer A, Schumacher CA, Wüst RC, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of te cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017;60(3):568–73.
60. Santos-Gallego CG, Vahl TP, Goliasch G, Picatoste B, Arias T, Ishikawa K, et al. Sphingosine-1-phosphate receptor agonist fingolimod increases myocardial salvage and decreases adverse postinfarction left ventricular remodeling in a porcine model of ischemia/reperfusion. Circulation. 2016;133(10):954–66.
61. Santos-Gallego C, Requena-Ibanez JA, Rodolfo San Antonio R et al. Empagliflozin induces a myocardial metabolic shift from glucose consumption to ketone metabolism that mitigates adverse cardiac remodeling and improves myocardial contractility. ACC-2018 Moderated Poster # 1318M-07.